When is CTMX's latest earnings report released?
The most recent financial report for Cytomx therapeutics, inc. (CTMX) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CTMX's short-term business performance and financial health. For the latest updates on CTMX's earnings releases, visit this page regularly.
Where does CTMX fall in the P/E River chart?
According to historical valuation range analysis, Cytomx therapeutics, inc. (CTMX)'s current price-to-earnings (P/E) ratio is 25.34, placing it in the Overvalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning optimistic. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of CTMX?
According to the latest financial report, Cytomx therapeutics, inc. (CTMX) reported an Operating Profit of -15.77M with an Operating Margin of -264.43% this period, representing a decline of 483.56% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is CTMX's revenue growth?
In the latest financial report, Cytomx therapeutics, inc. (CTMX) announced revenue of 5.96M, with a Year-Over-Year growth rate of -82.16%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does CTMX have?
At the end of the period, Cytomx therapeutics, inc. (CTMX) held Total Cash and Cash Equivalents of 35.21M, accounting for 0.22 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does CTMX go with three margins increasing?
In the latest report, Cytomx therapeutics, inc. (CTMX) did not achieve the “three margins increasing” benchmark, with a gross margin of 100%%, operating margin of -264.43%%, and net margin of -238.6%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CTMX's profit trajectory and future growth potential.
Is CTMX's EPS continuing to grow?
According to the past four quarterly reports, Cytomx therapeutics, inc. (CTMX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.09. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of CTMX?
Cytomx therapeutics, inc. (CTMX)'s Free Cash Flow (FCF) for the period is -15.42M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 25.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of CTMX?
The latest valuation data shows Cytomx therapeutics, inc. (CTMX) has a Price-To-Earnings (PE) ratio of 25.34 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
